Shots: Celltrion in collaboration with Poonglim Pharmatech will accelerate the development of its insulin pen biosimilar. The company will initiate the development of the insulin biosimilar in 2020 with an aim to commercially launch the product in 2025. Companies plans to develop a pen-type injection that can be administered up to 80 units at a […]Read More
Tags : Insulin Pen
Latest Posts
Categories
Related Topics
AbbVie
Acquire
Adults
Agreement
Amgen
approval
AstraZeneca
Bayer
Biosimilar
BMS
Collaborate
Collaborates
Collaboration
Commercialize
COVID-19
Develop
Development
Eli Lilly
Exclusive
FDA
Gilead
GSK
Janssen
Launches
License
License Agreement
Merck
Novartis
P-III
patients
Pfizer
receives
Regeneron
Report
reports
results
Roche
Sanofi
Signs
study
Takeda
the US FDA
Treat
Treatment
US